Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
2022 · Journal of Clinical Oncology · 301 citations
https://doi.org/10.1200/jco.22.00868
T
Tracy L. Rose
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
177
Papers
2.5K
Citations
22
h-index
35
i10-index
Tracy L. Rose is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Cancer, Hypoxia, and Metabolism & Renal cell carcinoma treatment. The author has an h-index of 22, co-authored 151 publications.
ORCID: 0000-0003-1411-2487Papers by this author
worksFibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
2021 · British Journal of Cancer · 185 citations
https://doi.org/10.1038/s41416-021-01488-6
Renal Cell Carcinoma
2024 · JAMA · 185 citations
https://doi.org/10.1001/jama.2024.12848
Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy
2018 · British Journal of Cancer · 61 citations
https://doi.org/10.1038/s41416-018-0229-0
Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity
2020 · Journal of Immunotherapy · 31 citations
https://doi.org/10.1097/cji.0000000000000338
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer
2024 · Nature Communications · 24 citations
https://doi.org/10.1038/s41467-024-48480-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat